Home » Why Micron Fell and Faces An Even Steeper Decline – The Daily Rundown

Why Micron Fell and Faces An Even Steeper Decline - The Daily Rundown

Why Micron Fell and Faces An Even Steeper Decline – The Daily Rundown

[widget id=”text-22″]

Why Micron Fell and Faces An Even Steeper Decline – The Daily Rundown

Michael Kramer and the clients of Mott Capital own shares of CELG and AAPL

Technology Smash

Unlock Deeper Insights with Exclusive Member-Only Video Content on The Market Chronicles YouTube Channel – Just $34.99/Month

The technology sector got hit pretty hard again, with the NASDAQ more than 1 percent at one point during the day. The good news is the index bounce along the uptrend.

nasdaq

Micron

There may not have been a tech stock hit harder today than Micron. The stock got some negative commentary out of Baird this morning, noting peak gross margins, while DRAM prices may be peaking, and an oversupply in NAND. I have talked about Micron and its low valuation over and over and over. We have spoken about Micron being a gross margin story. If gross margins are peaking and heading lower, then so too is this stock.  I know we focus a lot on the technical charts and that is because there is so much emotion in the stock, so technicals matter a great deal. But the gross margins and fundamentals of the business have always been a source of concern for me. That has still not changed.  The low valuation has also served as evidence of the skepticism in the stock by investors as well.

MU Chart

MU data by YCharts

So the big questions is where does the stock go now?  I do not think the selling is over. A bit of a turn around from my thoughts the other day, when I thought shares might rise.  But if we focus on the short-term, at least through earnings, the stock could see prices around $42.

micron

Apple

Apple fell hard too, but then again Apple has been up a bunch the last few weeks. I could see the stock falling to around $215, should the uptrend around $222 not hold.

aapl

AMD

Even AMD fell a bit today. Held support around $27.85. I’m done predicting where this thing goes. I can’t get it right.  I have probably gotten it right 1 or 2 times out of my last ten attempts. I’m guessing, but that is what it feels like.

amd

Biotech

These biotechs have also been slaughtered the last few days. The IBB is below support. I know. It had looked like it was heading to its 2015 highs. I still think it gets there. The break out seems like it may occur at a more measured pace. The uptrend is still solidly in place.

biotech

The charts on Celgene, Regeneron, Gilead, and Biogen still look solid. The only one I have a bit of concern over now is Gilead.

biotechs

China

The Chinese e-commerce stocks Alibaba and JD have gotten crushed, and I still think they are heading lower.  JD to $25.5 and Baba to $151.

alibaba jd

Macro

Don’t forget the big jobs reports tomorrow. ADP today came in a lighter than expected.  Tomorrow will be a big day for yields. A lighter Payroll number or higher unemployment rate could be reason enough for the Fed to hold off in a few weeks from raising rates again. Watch the ten-year tomorrow. It may be a big day.

ten year

That’s it!

-Mike

Subscriber Video’s

Michael Kramer is the Founder of Mott Capital and the creator of Reading the Markets.

2 Stocks To Consider If You Like Square

Big Biotech Breakout, Plus iPhone Super Cycle Maybe This Year!

Biotech And Semis Breaking Out?

FAANG’s Not Out Of The Woods But Getting Better

Verizon Nears Multiyear Break Out As 5G Data Speeds Near

Amazon May Plunge 10%

The Dollar May Soon Wreak Havoc On Oil And Gold

Inflation Runs Rampant Only In Fantasyland And That Is Good For Stocks

Tesla May Be Going Higher Regardless Of The Bid

Why The S&P 500 May Rise To 3,500

Why Apple May Rise By 50%

Facebook’s Growth Issue

Netflix Is Not Broken, Plus S&P May Rise To 3,000 Sooner Than You Think

[widget id=”text-23″]

Photo Credit Via Flickr

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

#technology #micron #amd #apple #biotech #alibaba #jd

Add your email to The Market Chronicles' growing list of daily readers. A FREE market commentary on the trading day's most critical and least apparent events!

Add your email to The Market Chronicles' growing list of daily readers. A FREE market commentary on the trading day's most critical and least apparent events!